Sign up for the Race/Related Newsletter join a deep and provocative exploration of race identity and society with New York Times journalists. Get it sent to your inbox.
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced it has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) SingleDose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex Injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC.
According to IQVIA sales data for the 12-month period ending November 2022, the Bumex Injection, 0.25 mg/mL market achieved annual sales of approximately $16.5 million.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
